Project Grant HT9425261E111
Award Date 5/15/26
Completion Date 5/14/29
Dollars Obligated $559K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tacoma, WA 98402, USA
Similar Awards
- Federal Grant Award Summary The Geneva Foundation received a $1,009,750 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded August 1, 2025, for a three-year performance period ending July 31, 2028. The award supports genomic and functional characterization of chemoresistance in small cell lung cancer, a research initiative conducted at the foundation's facility in Tacoma, Washington. This project contributes to...
- Federal Project Grant Award Summary The Geneva Foundation received a $909,510 Project Grant awarded May 1, 2025, by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support precision therapy research for the eradication of brain metastatic breast cancer. The three-year award, with an ultimate completion date of April 30, 2028, will be performed at the foundation's Tacoma, Washington facility. This research initiative aligns with the...
- Federal Grant Award Summary The Geneva Foundation received a $488,276 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective April 1, 2026 through March 31, 2029. This research initiative focuses on developing antagonism-enforced braking system CAR T-cells (chimeric antigen receptor T-cell therapy) for the treatment of TP53-mutant breast cancer. The project represents DHA's commitment to advancing innovative...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a project grant totaling $747,394 under the Military Medical Research and Development program (CFDA 12.420) for the period April 1, 2026 through March 31, 2029. The award funds research and development of antagonism-enforced braking system CAR T-cells (chimeric antigen receptor T-cell therapy) targeting TP53-mutant breast cancer. This research initiative represents the DHA's investment in innovative...
- Federal Project Grant Award Summary The Geneva Foundation received a $487,800 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective October 1, 2025 through September 30, 2027. The award funds research to define the cellular origins and molecular vulnerabilities of Notch-driven lymphomas. This research initiative contributes to the Defense Health Agency's broader mission of transforming healthcare for service members...
- Federal Project Grant Award Summary The Defense Health Agency awarded The Geneva Foundation a $4.4 million project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on extracorporeal immunomodulation techniques designed to reduce inflammation following severe burns, inhalation injury, and septicemia. The award, effective November 1, 2025, through October 31, 2028, supports a three-year research initiative focused on developing innovative...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a $575,968 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2025, for an efficacy and feasibility trial of a portable near-infrared hematoma imager designed to detect intracranial hemorrhage in acute care settings. The 24-month project, concluding September 29, 2027, will be conducted in Tacoma, Washington. This award supports translational research...
- Federal Project Grant Award Summary The Geneva Foundation received a $4.82 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded July 15, 2025, with a completion date of July 14, 2028. The award funds the development of a patient-matched segmental defect implant system with mechanobiologic activation and antimicrobial coating designed to treat severe fractures. This research initiative represents an...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $560,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period of September 1, 2026, through August 31, 2028. The award supports the development of novel digenic combination therapies for pancreatic cancer treatment, representing a two-year research initiative conducted at DFCI's Boston, Massachusetts facility. This project...
- The Geneva Foundation was awarded a $362,100 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program to conduct research toward the dual targeting of HER2 and androgen receptor in patients with high-risk, hormone-naive prostate cancer with curative intent. The two-year grant project period runs from June 1, 2022 to May 31, 2024. Through this funding, The Geneva Foundation will perform applied medical research investigating...